Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma
- PMID: 16804116
- PMCID: PMC1895596
- DOI: 10.1182/blood-2006-02-005488
Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma
Abstract
Waldenström macroglobulinemia (WM) is a B-cell malignancy characterized by the ability of the B-cell clone to differentiate into plasma cells. Although the clinical syndrome and the pathologic characteristics are well defined, little is known about its biology and controversy still exists regarding its cell of origin. In this gene-expression study, we compared the transcription profiles of WM with those of other malignant B cells including (chronic lymphocytic leukemia [CLL] and multiple myeloma [MM]) as well as normal cells (peripheral-blood B cells and bone marrow plasma cells). We found that WM has a homogenous gene expression regardless of 6q deletion status and clusters with CLL and normal B cells on unsupervised clustering with very similar expression profiles. Only a small gene set has expression profiles unique to WM compared to CLL and MM. The most significantly up-regulated gene is IL6 and the most significantly associated pathway for this set of genes is MAPK signaling. Thus, IL6 and its downstream signaling may be of biologic importance in WM. Further elucidation of the role of IL-6 in WM is warranted as this may offer a potential therapeutic avenue.
Figures
Similar articles
-
Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals.Leukemia. 2007 Mar;21(3):541-9. doi: 10.1038/sj.leu.2404520. Epub 2007 Jan 25. Leukemia. 2007. PMID: 17252022
-
Genomics and proteomics in multiple myeloma and Waldenström macroglobulinemia.Curr Opin Hematol. 2007 Jul;14(4):369-74. doi: 10.1097/MOH.0b013e3281ddb2b8. Curr Opin Hematol. 2007. PMID: 17534163 Review.
-
Diagnostic and clinical considerations in concomitant bone marrow involvement by plasma cell myeloma and chronic lymphocytic leukemia/monoclonal B-cell lymphocytosis: a series of 15 cases and review of literature.Arch Pathol Lab Med. 2013 Apr;137(4):503-17. doi: 10.5858/arpa.2011-0696-OA. Arch Pathol Lab Med. 2013. PMID: 23544940 Review.
-
Gene Expression Profiling Reveals Aberrant T-cell Marker Expression on Tumor Cells of Waldenström's Macroglobulinemia.Clin Cancer Res. 2019 Jan 1;25(1):201-209. doi: 10.1158/1078-0432.CCR-18-1435. Epub 2018 Oct 2. Clin Cancer Res. 2019. PMID: 30279229 Free PMC article.
-
Frequent somatic mutations in D and/or JH segments of Ig gene in Waldenström's macroglobulinemia and chronic lymphocytic leukemia (CLL) with Richter's syndrome but not in common CLL.Blood. 1995 Apr 1;85(7):1913-9. Blood. 1995. PMID: 7703494
Cited by
-
Review of BCL2 inhibitors for the treatment of Waldenström's macroglobulinaemia and non-IgM lymphoplasmacytic lymphoma.Front Oncol. 2024 Nov 4;14:1490202. doi: 10.3389/fonc.2024.1490202. eCollection 2024. Front Oncol. 2024. PMID: 39558954 Free PMC article. Review.
-
Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia.Curr Hematol Malig Rep. 2024 Aug;19(4):163-174. doi: 10.1007/s11899-024-00730-1. Epub 2024 Jul 6. Curr Hematol Malig Rep. 2024. PMID: 38970645 Review.
-
Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination.J Hematol Oncol. 2022 Jun 3;15(1):75. doi: 10.1186/s13045-022-01295-3. J Hematol Oncol. 2022. PMID: 35659041 Free PMC article. Review.
-
Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance.Diagnostics (Basel). 2022 Apr 12;12(4):969. doi: 10.3390/diagnostics12040969. Diagnostics (Basel). 2022. PMID: 35454017 Free PMC article. Review.
-
Case Report: Chronic Lymphocytic Leukemia With Recurrent Complement-Mediated Thrombotic Microangiopathy and C3 Glomerulonephritis.Front Med (Lausanne). 2022 Feb 10;9:813439. doi: 10.3389/fmed.2022.813439. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35223908 Free PMC article.
References
-
- Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's macroglobulinemia. Semin Oncol. 2003;30: 110-115. - PubMed
-
- Kriangkum J, Taylor BJ, Strachan E, et al. Impaired class switch recombination (CSR) in Waldenstrom macroglobulinemia (WM) despite apparently normal CSR machinery. Blood. 2006; 107: 2920-2027. - PubMed
-
- Kriangkum J, Taylor BJ, Treon SP, Mant MJ, Belch AR, Pilarski LM. Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood. Blood. 2004;104: 2134-2142. - PubMed
-
- Ackroyd S, O'Connor SJ, Owen RG. Rarity of IgH translocations in Waldenstrom macroglobulinemia. Cancer Genet Cytogenet. 2005;163: 77-80. - PubMed
-
- Schop RF, Kuehl WM, Van Wier SA, et al. Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood. 2002;100: 2996-3001. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
